<DOC>
	<DOCNO>NCT00400361</DOCNO>
	<brief_summary>This study determine maximum tolerate dose pharmacokinetic profile R1507 patient metastatic locally advanced malignant solid tumor , non-Hodgkin 's lymphoma Hodgkin 's lymphoma . Groups patient sequentially enrol receive ascending dose R1507 either weekly three-weekly intravenous infusion . The start dose 1mg/kg iv dose regimen escalate subsequent group patient satisfactory assessment safety , tolerability pharmacokinetics previous dose . The anticipated time study treatment disease progression dose-limiting toxicity , target sample size &lt; 100 individual .</brief_summary>
	<brief_title>A Multiple Ascending Dose Study R1507 Patients With Advanced Solid Tumors .</brief_title>
	<detailed_description />
	<criteria>adult patient , &gt; =18 year age ; solid neoplasm , nonHodgkin 's lymphoma Hodgkin 's lymphoma ; metastatic locally advanced disease , curable currently available treatment . severe , uncontrolled systemic disease ; patient require treatment glucocorticoid immunosuppressive treatment within last 6 month ; patient diabetes mellitus .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>